Incanthera (AQSE:INC) Change In Receivables : £0.08 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Change In Receivables?

Incanthera's change in receivables for the quarter that ended in Sep. 2023 was £0.03 Mil. It means Incanthera's Accounts Receivable declined by £0.03 Mil from Mar. 2023 to Sep. 2023 .

Incanthera's change in receivables for the fiscal year that ended in Mar. 2023 was £0.06 Mil. It means Incanthera's Accounts Receivable declined by £0.06 Mil from Mar. 2022 to Mar. 2023 .

Incanthera's Accounts Receivable for the quarter that ended in Sep. 2023 was £0.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Incanthera's liquidation value for the six months ended in Sep. 2023 was £-0.81 Mil.

Incanthera Change In Receivables Historical Data

The historical data trend for Incanthera's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Change In Receivables Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Change In Receivables

-0.01

-0.02

0.02

0.06

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Receivables	Get a 7-Day Free Trial			-0.09	0.10	-	0.05	0.03

Incanthera Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.08 Mil.

Incanthera (AQSE:INC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Incanthera's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.033	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Incanthera's accounts receivable are only considered to be worth 75% of book value:

Incanthera's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	-0.004	-	0.828	+	0.75 * 0.033	+	0.5 * 0
=	-0.81

Incanthera Change In Receivables Related Terms

Thank you for viewing the detailed overview of Incanthera's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines